Anastrozole
CLINICAL USE
Treatment of breast cancer in post-
menopausal women
DOSE IN NORMAL RENAL FUNCTION
1 mg daily
PHARMACOKINETICS
293.4
40
No data
40–50/Probably
unchanged
DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
Dialysed. Dose as in normal renal
function
Dialysed. Dose as in normal renal
function
Dialysed. Dose as in normal renal
function
Dialysed. Dose as in normal renal
function
IMPORTANT DRUG INTERACTIONS
concomitant administration as would
negate pharmacological action
administration
ADMINISTRATION
Reconstition
–
Route
Oral
Rate of Administration
–
Comments
–
OTHER INFORMATION
the liver; only 10% of unchanged drug and
60% of metabolites (largely inactive) are
excreted in the urine
decreases proportionally with creatinine
clearance, the reduction in renal clearance
does not affect total body clearance of
anastrozole. According to the American
SPC a dose reduction is not required in
renal impairment
the use of anastrozole in patients with
GFR<20 mL/min